GH Research PLC GHRS
19.10 USD -0.16 (-0.83%)
Nov 10, 2026, 12:27 PM EST
18.83 Day range 19.85
12.04 52-week range 31.44
- YTD
- +50.40%
- 1 year
- +41.07%
News
benzinga.com Guggenheim Maintains Buy on GH Research, Raises Price Target to $40 Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
benzinga.com Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40 Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $39 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.- benzinga.com GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15)…
benzinga.com Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44 Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overweight rating and announces Price Target of $44.
benzinga.com Why Is GH Research Stock Trading Higher on Thursday? GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
benzinga.com GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World…
benzinga.com HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65 HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and lowers the price target from $70 to $65.
benzinga.com These Analysts Revise Their Forecasts On GH Research After Q1 Results GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.- benzinga.com Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35 Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $25 to $35.
- benzinga.com Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39 Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and lowers the price target from $42 to $39.
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 63.16 percent decrease over losses of…
- benzinga.com 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive Health officials explored restricting specific antidepressants among SSRI drugs-sources
- benzinga.com GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
benzinga.com Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
benzinga.com Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.- benzinga.com 'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
- benzinga.com GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
- benzinga.com Citizens Maintains Market Outperform on GH Research, Raises Price Target to $42 Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and raises the price target from $39 to $42.
benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $32 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $31 to $32.- benzinga.com GH Research Q4 EPS $(0.23) Beats $(0.28) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.56 percent. This is a 35.29 percent decrease over losses of $(0.17)…
benzinga.com HC Wainwright & Co. Maintains Buy on GH Research, Raises Price Target to $70 HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $70.- benzinga.com RBC Capital Maintains Outperform on GH Research, Raises Price Target to $40 RBC Capital analyst Brian Abrahams maintains GH Research (NASDAQ:GHRS) with a Outperform and raises the price target from $33 to $40.
- benzinga.com Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $39 Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $39.
- benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $29 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $19 to $29.
benzinga.com Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December 
benzinga.com Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday 
benzinga.com US Stocks Higher; Dow Jumps 250 Points 
benzinga.com FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in treatment-resistant depression, clearing the path toward Phase 3 trials planned for 2026.
benzinga.com Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story.) U.S. stock futures rose in the first full trading week of the year on Monday after…
benzinga.com NextEra Energy, GH Research And 3 Stocks To Watch Heading Into Monday - benzinga.com FDA Has Lifted The Clinical Hold On GH Research's Investigational New Drug Application For GH001, Phase 3 Initiation Targeted For 2026 GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - benzinga.com GH Research To Provide Update On FDA IND Status And Phase 3 Program For GH001 in Treatment-Resistant Depression On January 5, 2026, At 7:00am EST GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported…
- benzinga.com HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $35 HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and lowers the price target from $40 to $35.
benzinga.com GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 2.95 percent. This is unchanged from the same period last year.
benzinga.com Depression-Focused GH Research Shares Could See Significant Upside: Analyst GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential.
benzinga.com This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Needham Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $19 Needham analyst Ami Fadia initiates coverage on GH Research (NASDAQ:GHRS) with a Buy rating and announces Price Target of $19.
- benzinga.com GH Research to Present Long-Term Data on Depression Treatment at 38th European Neuropsychopharmacology Congress GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
- benzinga.com GH Research Q2 EPS $(0.15) Beats $(0.21) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 30.23 percent. This is a 25 percent increase over losses of $(0.20)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com GH Research Reports 73% Remission At 6 Months In TRD Trial; FDA Engagement On GH001 IND Ongoing, Global Pivotal Launch Set For 2026 Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no…
- benzinga.com 'House Votes To Let VA Doctors Recommend Medical Marijuana To Military Veterans And To Support Psychedelics Research' - Marijuana Moment https://www.marijuanamoment.net/house-votes-to-let-va-doctors-recommend-medical-mari
- benzinga.com "RFK Says Trump Administration Could Provide Psychedelic Therapy To Military Veterans 'Within 12 Months'" - Marijuana Moment https://www.marijuanamoment.net/rfk-says-trump-administration-could-provide-psychedelic-therapy-to-military-veterans-within-12-months/